Avacta: Mark Goldberg

Avacta has appointed Mark Goldberg as a non-executive director to its board. Goldberg is a medical oncologist and haematologist on the faculty of Brigham & Women’s Hospital and Harvard Medical School.

He serves on the boards of directors of ImmunoGen, Idera Pharmaceuticals, GlycoMimetics, Walden Biosciences, and Blueprint Medicines. Goldberg served on the board of directors of Audentes Therapeutics up to its acquisition by Astellas Pharma in 2020, and on the executive management team of Synageva Biopharma from 2011 to 2014. From 1996 to 2011, he held management roles of increasing responsibility, including senior vice president of clinical development, at Genzyme.

Goldberg is a long-time American Cancer Society and ACS Cancer Action Network volunteer. He is the past-chair of the Eastern New England Area Board of the American Cancer Society, and currently serves as a member of its national board of directors